Non-Interventional Study to Establish Consensus on Management of Metastatic Hormone-Sensitive Prostate Cancer Patients

The purpose of this study is to establish an expert consensus recommendations on managing patients with mHSPC in South Korea, and to provide clinicians with a comprehensive guide to support their clinical decision making. There are no secondary objectives for this study.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Metastatic Hormone-sensitive Prostate Cancer Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Male Urogenital Diseases Neoplasms Neoplasms by Site Urogenital Diseases Urogenital Neoplasms Urologic Diseases Urologic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

KR82001

Seoul, South Korea

About this study

Data collection for this study will be conducted through 2 rounds of web-based surveys of health care professionals (HCPs). A meeting with the panelists will be held as a 3rd round if a consensus for pre determined key questions is not achieved after the 2 rounds of the survey.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Urologist from university hospitals in South Korea.
Has a minimum 10 years of practice experience (experience as a military or public health doctor could be considered practice experience)
Sees a minimum of 50 mHSPC patients in a year.
At least 10 publications in SCIE (Science Citation Index Expanded) journals in the past 5 years.

Exclusion criteria

Urologist in private practice.

Treatment and study plan

No intervention

Other

No investigational drug will be administered to participants in this study.

Primary outcomes

Treatment plans for patients with mHSPC

Time frame: Up to 7 days

Treatment plans for patients with mHSPC within the local healthcare environment will be collected via online surveys and a consensus meeting will be held if required.

Sponsors and collaborators

Lead sponsor

Astellas Pharma Korea, Inc.

Industry

Registry information

Official study title

A Non-Interventional, Modified Delphi Study to Establish Consensus Recommendations on the Optimal Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Patients in South Korea

Important dates

Study start: 2024
Primary completion: 2024
Study completion: 2024
First posted: Jun 11, 2024
Registry last updated: Nov 21, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed